These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 30009577

  • 1. (-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
    Shin S, Kim MK, Jung W, Chong Y.
    Phytother Res; 2018 Oct; 32(10):2086-2096. PubMed ID: 30009577
    [Abstract] [Full Text] [Related]

  • 2. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR, Beaulieu LM, Carter JC, Church FC.
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [Abstract] [Full Text] [Related]

  • 3. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 4. Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells.
    Kim MH, Jung MA, Hwang YS, Jeong M, Kim SM, Ahn SJ, Shin BA, Ahn BW, Jung YD.
    Eur J Pharmacol; 2004 Mar 08; 487(1-3):1-6. PubMed ID: 15033370
    [Abstract] [Full Text] [Related]

  • 5. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.
    Clin Exp Metastasis; 1996 May 08; 14(3):297-307. PubMed ID: 8674284
    [Abstract] [Full Text] [Related]

  • 6. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
    Han YC, Zeng XX, Wang R, Zhao Y, Li BL, Song M.
    Ai Zheng; 2007 Jan 08; 26(1):48-53. PubMed ID: 17222367
    [Abstract] [Full Text] [Related]

  • 7. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
    Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP.
    Cancer; 1995 Sep 15; 76(6):998-1005. PubMed ID: 8625226
    [Abstract] [Full Text] [Related]

  • 8. Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
    Dong-Le Bourhis X, Lambrecht V, Boilly B.
    Br J Cancer; 1998 Sep 15; 77(3):396-403. PubMed ID: 9472634
    [Abstract] [Full Text] [Related]

  • 9. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
    Sliva D, Rizzo MT, English D.
    J Biol Chem; 2002 Feb 01; 277(5):3150-7. PubMed ID: 11689575
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.
    Fortenberry YM, Brandal SM, Carpentier G, Hemani M, Pathak AP.
    PLoS One; 2016 Feb 01; 11(10):e0164288. PubMed ID: 27755560
    [Abstract] [Full Text] [Related]

  • 12. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
    Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S, Kordula T.
    Mol Cancer Res; 2008 Sep 01; 6(9):1469-77. PubMed ID: 18819934
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M, Mourah S, Dosquet C.
    Int J Cancer; 2011 Mar 15; 128(6):1280-92. PubMed ID: 20473943
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human breast cancer cell (MBA-MD-231) invasion by the Ea4-peptide of rainbow trout pro-IGF-I.
    Siri S, Chen MJ, Chen TT.
    J Cell Biochem; 2006 Dec 01; 99(5):1363-73. PubMed ID: 16795042
    [Abstract] [Full Text] [Related]

  • 16. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
    Webb DJ, Thomas KS, Gonias SL.
    J Cell Biol; 2001 Feb 19; 152(4):741-52. PubMed ID: 11266465
    [Abstract] [Full Text] [Related]

  • 17. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
    Sliva D, English D, Lyons D, Lloyd FP.
    Biochem Biophys Res Commun; 2002 Jan 11; 290(1):552-7. PubMed ID: 11779207
    [Abstract] [Full Text] [Related]

  • 18. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
    Ho YC, Yang SF, Peng CY, Chou MY, Chang YC.
    J Oral Pathol Med; 2007 Nov 11; 36(10):588-93. PubMed ID: 17944751
    [Abstract] [Full Text] [Related]

  • 19. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L, Han X.
    Biomed Pharmacother; 2013 Mar 11; 67(2):179-82. PubMed ID: 23201006
    [Abstract] [Full Text] [Related]

  • 20. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
    Belkacemi L, Lam E, Caldwell JD, Siemens DR, Graham CH.
    Exp Cell Res; 2006 Jun 10; 312(10):1685-92. PubMed ID: 16564525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.